FDA Approves Unknown Drug — ASPIRO

# FDA Approves ASPIRO's Generic Drug Application ASPIRO has received FDA approval for its abbreviated new drug application (ANDA 220124), expanding the company's generic pharmaceutical portfolio and positioning it to capture market share in an established therapeutic category. The approval enhances ASPIRO's competitive standing in the generic drug market and is expected to drive revenue growth through increased market penetration and potential cost savings for patients and payers.